Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Forte Biosciences, Inc. (FBRX) EBIAT (2016 - 2020)

Forte Biosciences (FBRX) has disclosed EBIAT for 5 consecutive years, with -$4.6 million as the latest value for Q4 2020.

  • On a quarterly basis, EBIAT fell 109.36% to -$4.6 million in Q4 2020 year-over-year; TTM through Dec 2020 was -$46.5 million, a 200.28% decrease, with the full-year FY2024 number at -$35.5 million, down 12.71% from a year prior.
  • EBIAT was -$4.6 million for Q4 2020 at Forte Biosciences, up from -$5.1 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of $48.9 million in Q4 2019 to a low of -$34.8 million in Q2 2020.
  • A 5-year average of -$6.1 million and a median of -$8.2 million in 2016 define the central range for EBIAT.
  • Peak YoY movement for EBIAT: surged 349.27% in 2019, then plummeted 5417.62% in 2020.
  • Forte Biosciences' EBIAT stood at -$8.4 million in 2016, then fell by 28.55% to -$10.8 million in 2017, then plummeted by 80.89% to -$19.6 million in 2018, then surged by 349.27% to $48.9 million in 2019, then crashed by 109.36% to -$4.6 million in 2020.
  • Per Business Quant, the three most recent readings for FBRX's EBIAT are -$4.6 million (Q4 2020), -$5.1 million (Q3 2020), and -$34.8 million (Q2 2020).